Cytomegalovirus Infection Market Report
The report on Global Cytomegalovirus Infection Market is segmented By Drug Type (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir), By Infection Type (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) and Region. The report also covers COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global cytomegalovirus infection market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The report on Global Cytomegalovirus Infection Market is segmented By Drug Type (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir), By Infection Type (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, Others), By Distribution Channel ...
The Global Cytomegalovirus Infection Market is projected to grow from USD 520.5 million in 2020 to USD 751.2 million by 2026 at a CAGR of over 6.3% during the forecast period.
Figure: Global Cytomegalovirus Infection Market Size, 2020-2026 (USD Million)
Wish to get a sample report? Click here.
Cytomegalovirus (CMV) infection is a common herpes virus infection with various symptoms that occurs in people of all types of ages worldwide. This viral infection is communicable and can be easily spread through bodily fluids including urine, semen, blood, and breast milk. This infection can be spread easily through urine or saliva and the people infected with this virus may have the virus in the urine or saliva for months. The diseases can further be transferred from pregnant women to the baby during the delivery. Blood transfusion and infected organ transplant is another mode of disease transmission.
Key players operating in the global cytomegalovirus infection market are-
The growing awareness among the public related to herpes virus infection is one of the key factors driving the market growth. Increasing awareness associated with rare diseases, high purchasing power, improving healthcare infrastructure, and government support for novel treatment against rare genetic diseases, further propels the diagnosis rate of this virus across the globe. However, serious side effects and risks related to cytomegalovirus drugs are expected to hinder the industry expansion.
Based on drug type, the global cytomegalovirus infection market has been segmented into cidofovir, foscarnet, valganciclovir, and ganciclovir.
By region, the North American market garnered the largest market share in 2020 and is likely to register a considerable CAGR during the review period. This can be attributed to high cost and better treatment in the US, extensive government funding, the strong regulatory framework for promoting cellular therapy development, and the presence of a large number of key biotechnology companies, thus accelerates the regional market growth.
The COVID-19 pandemic has substantially affected the cytomegalovirus infection industry due to lack of patient visits to healthcare facilities such as hospitals and clinics on account of restricted movement and strict social distance norms. Moreover, due to rising spread of coronavirus, there is limited workforce causing staffing issues. This further affects cytomegalovirus infection market by cancellation of appointments for primary care at clinics.
Get the full scope of the report? Register Here
Here is the list of the group of customers that the Cytomegalovirus infection market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The cytomegalovirus infection market size is expected to reach USD 751.2 million in the foreseeable future.
ViroPharma (The US), Chimerix, Inc. (The US), Vical, Inc. (The US), AiCuris Anti-infective Cures GmbH (Germany), Merck & Co., Inc. (The US), GlaxoSmithKline plc (UK), F. Hoffmann-La Roche AG (Switzerland), Clinigen Group PLC (UK), Fresenius Kabi Canada (Canada), Genentech Inc. (The US), and Gilead Sciences (The US) are among the key players in the cytomegalovirus infection market.
The cytomegalovirus infection market is expected to grow at an impressive growth of 6.3% CAGR in the coming years.
Growing awareness among the public related to herpes virus infection, increasing awareness associated with rare diseases, high purchasing power, improving healthcare infrastructure, and government support for novel treatment against rare genetic diseases are the factors driving the growth of cytomegalovirus infection market.
North American market garnered the largest market share in 2020 and is likely to register a considerable CAGR during the review period.
The ganciclovir segment held the highest share in 2020 and is likely to register a healthy CAGR during the review period.
Cytomegalovirus Infection treatment companies, Hospitals, Diagnostic Centers And Laboratories, Academic Institutions, Research Centers & Organizations are the target audience in the cytomegalovirus infection market.